Active Ingredients: Azithromycin
Methods This study analyzed 484 samples collected at delivery as part of a randomized, partially placebo controlled clinical trial, conducted in rural Malawi between. The study included pregnant women regardless of their gravidity or HIV-infection status.
The main outcome was the prevalence of peripheral Plasmodium falciparum malaria at delivery diagnosed with a real-time polymerase chain reaction PCR assay.
When only HIV-negative participants were analyzed, the corresponding figures were 0. Trial Registration ClinicalTrials.
Azithromycin and its placebo were provided free of charge by Pfizer Inc New York. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Azithromycin and its placebo used in the study were provided free of charge by Pfizer Inc New York, which had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Introduction Malaria is one of the most important preventable causes of poor maternal health and adverse birth outcomes.SammyNop - 10.
In sub-Saharan Africa SSA, an estimated 25 million pregnant women are in danger of Plasmodium falciparum infections every year. Fortunately, much of the malaria-associated morbidity and mortality can be prevented by intermittent preventive treatment in pregnancy IPTp, and 35 of 45 sub-Saharan African countries had adopted IPTp with sulfadoxine-pyrimethamine SP as a national policy by the end of.
However, the effectiveness of the standard two-dose SP IPTp is under threat due to increasing SP-resistance, declined malaria immunity among women infected with human immunodeficiency virus HIV, possibly too long treatment interval, and difficulties in practical implementation —.
Thus, new antimalarial regimens for IPTp are needed, but finding an alternative to SP has proven difficult. Increasing the dosing frequency of SP has been considered as one possibility to improve the effectiveness of SP IPTp while alternative regimens are being explored.
At least four trials have tested the efficacy of an IPTp regimen that contains monthly SP-dosing —.
However, three of these trials focused on defined risk groups and not an unselected population of pregnant women, which typically comprises the actual target group for IPTp —.
A Kenyan and a Malawian study enrolled participants in their first or second pregnancy,, and a Zambian sample included only HIV-positive women. These three trials, in aggregate, suggest that monthly SP results in less placental and peripheral maternal malaria at delivery and a higher birth weight among HIV-positive primi- and secundigravidae.
However, there is no conclusive evidence of the benefits of monthly SP for HIV-negative women, for HIV-positive multigravidae, or for a population comprising of both HIV-positive and —negative women of different gravidities.